Dr. Shiwei Duan PhD
Professor, School of Medicine, Hangzhou City University, Zhejiang, China · China
Editorial leadership for Journal of Family Medicine ISSN 2640-690X
Research interests
- Epigenomics / Dna Methylation / Noncoding Rnas Pharmacogenomics In Cancer Therapy Genetic Variation
- Gene Expression (Eqtls) Complex Disease Genomics Biomarker Discovery & Translational Epigenetics Stem Cell Genomics
- Mitochondrial Profiling
Biography
Dr. Shiwei Duan is a leading researcher in epigenetics and epigenomics, currently serving as Professor of Medicine at Hangzhou City University. She earned her PhD in Molecular Cell Biology from Shanghai Jiao Tong University in 2005 and has held research appointments in internationally respected institutions. Duan’s research spans a broad array of topics including DNA/RNA methylation, noncoding RNAs, genetic variation, and their roles in chemotherapy response, cancer, and complex human diseases. According to Google Scholar, she has over 11,000 citations, an h-index above 50, and a robust i10-index, demonstrating sustained academic influence. Her work includes both fundamental discoveries (e.g., linking SNPs to gene expression, evaluation of variation across populations) and more translational studies addressing biomarkers, therapeutic targets, and molecular mechanisms of disease. Dr. Duan is actively publishing and collaborating, and her expertise in epigenomics is widely recognized in cancer research, pharmacogenomics, and complex disease genomics. She also supervises postgraduate work, contributes to peer review, and participates in academic leadership in molecular pathology and genomics.
Education Details
- PhD, Molecular Cell Biology – Shanghai Jia Tong University, 2005
- MS (Applied Biochemistry) – East China University of Science and Technology, ~2002
- BS (Biochemistry) – East China University of Science and Technology, ~1997
Professional Background
- Professor, School of Medicine, Hangzhou City University, Zhejiang, China
- Editor / Researcher in epigenetics, cancer genomics, pharmacogenomics
- Collaborated internationally; work includes genetic association, miRNA, methylation, noncoding RNA function in disease contexts
Current Research Projects
- Exploring epigenetic biomarkers (DNA methylation, noncoding RNAs) in cancer and complex diseases
- Genetic / transcriptomic variation studies, population genetics relating to disease susceptibility and therapeutic response
- Mitochondrial mutation profiling in stem cells — example: “Exploring haematopoietic stem cell dynamics…” (2024)
Selected publications
- Disulfidptosis: a new target for metabolic cancer therapy 2023 cited 247×
- Nanopore sequencing technology and its applications 2023 cited 60×
- Targeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies 2023 cited 47×
- A significant association between BDNF promoter methylation and the risk of drug addiction 2016 cited 45×
- miR-940 is a new biomarker with tumor diagnostic and prognostic value 2021 cited 35×
- Elevated CpG island methylation of GCK gene predicts the risk of type 2 diabetes in Chinese males 2014 cited 35×
Ranked by citation impact (Crossref) where available, newest otherwise · verified via ORCID.
Considering JFM for your work?
This journal is guided by Dr. Shiwei Duan (Professor, School of Medicine, Hangzhou City University, Zhejiang, China) and a peer-review board of practising researchers. Open access, author-retained copyright (CC BY), and a clear editorial process.